![Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes](https://pharmashots.com/public/images/20211115235833_ogImage_43.jpg)
Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps to Treat Type 1 or Type 2 Diabetes
![Novo Nordisk receives FDA approval for Fiasp (insulin aspart injection), a new fast-acting mealtime insulin | theindependentbd.com Novo Nordisk receives FDA approval for Fiasp (insulin aspart injection), a new fast-acting mealtime insulin | theindependentbd.com](https://www.theindependentbd.com/assets/news_images/Novo-Nordisk-receives-FDA-approval.jpg)
Novo Nordisk receives FDA approval for Fiasp (insulin aspart injection), a new fast-acting mealtime insulin | theindependentbd.com
![Laboratorio Novo Nordisk presenta en Chile insulina FIASP, la insulina aspártica de más rápida acción del mercado. – Fundación Mi Diabetes Laboratorio Novo Nordisk presenta en Chile insulina FIASP, la insulina aspártica de más rápida acción del mercado. – Fundación Mi Diabetes](https://www.midiabetes.cl/wp-content/uploads/2021/06/c6222344281545c6ac217d45ccec4e35-1170x780.jpeg)